{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T06:18:27Z","timestamp":1783059507653,"version":"3.54.6"},"reference-count":64,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100015763","name":"Szegedi Tudom\u00e1nyegyetem","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015763","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011019","name":"Nemzeti Kutat\u00e1si Fejleszt\u00e9si \u00e9s Innov\u00e1ci\u00f3s Hivatal","doi-asserted-by":"publisher","award":["K_146148"],"award-info":[{"award-number":["K_146148"]}],"id":[{"id":"10.13039\/501100011019","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ejps.2026.107538","type":"journal-article","created":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T15:48:10Z","timestamp":1776959290000},"page":"107538","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Development of inhalable extra-fine particles of vancomycin for the treatment of pulmonary methicillin-resistant Staphylococcus aureus infections"],"prefix":"10.1016","volume":"221","author":[{"given":"Petra","family":"Party","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilay","family":"G\u00f6ksel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1rp\u00e1d","family":"Farkas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u00f3ra","family":"Par\u00f3czai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katalin","family":"Buri\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Ambrus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2026.107538_bib0003","article-title":"Inhalable vancomycin-loaded lactose microparticles for treatment of MRSA pneumonia","volume":"80","author":"Abdelaziz","year":"2023","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.ejps.2026.107538_bib0005","series-title":"Nanoencapsulation Technologies for the Food and Nutraceutical Industries","first-page":"346","article-title":"10 - Nanocapsules formation by nano spray drying","author":"Arpagaus","year":"2017"},{"key":"10.1016\/j.ejps.2026.107538_bib0004","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.ijpharm.2018.05.037","article-title":"Nano spray drying for encapsulation of pharmaceuticals","volume":"546","author":"Arpagaus","year":"2018","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2026.107538_bib0006","first-page":"26","article-title":"Development of a carrier free dry powder inhalation formulation of ketotifen for pulmonary drug delivery","author":"Azari","year":"2020","journal-title":"Drug Res."},{"key":"10.1016\/j.ejps.2026.107538_bib0007","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1080\/10837450.2021.1915331","article-title":"Preparation and evaluation of vancomycin spray-dried powders for pulmonary delivery","volume":"26","author":"Bahrainian","year":"2021","journal-title":"Pharm. Dev. Technol."},{"key":"10.1016\/j.ejps.2026.107538_bib0008","doi-asserted-by":"crossref","DOI":"10.3390\/ph17010075","article-title":"A novel combined dry powder inhaler comprising nanosized ketoprofen-embedded mannitol-coated microparticles for pulmonary inflammations: development, in vitro\u2013in silico characterization, and cell line evaluation","volume":"17","author":"Banat","year":"2024","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejps.2026.107538_bib0009","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.ejpb.2008.09.018","article-title":"Nano-salbutamol dry powder inhalation: a new approach for treating broncho-constrictive conditions","volume":"71","author":"Bhavna","year":"2009","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejps.2026.107538_bib0010","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S0168-3659(00)00362-X","article-title":"Influence of formulation excipients and physical characteristics of inhalation dry powders on their aerosolization performance","volume":"70","author":"Bosquillon","year":"2001","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejps.2026.107538_bib0001","unstructured":"2.9.34. Bulk density of powders, In European Pharmacopoeia 11.5; 2024; pp. 5830\u20135833."},{"key":"10.1016\/j.ejps.2026.107538_bib0011","doi-asserted-by":"crossref","first-page":"425","DOI":"10.35333\/jrp.2020.165","article-title":"Nano-embedded microparticles based dry powder inhaler for lung cancer treatment","volume":"24","author":"Chishti","year":"2020","journal-title":"J. Res. Pharm."},{"key":"10.1016\/j.ejps.2026.107538_bib0014","first-page":"1","article-title":"\u00faj formul\u00e1l\u00e1si strat\u00e9gi\u00e1k a porinhal\u00e1ci\u00f3s k\u00e9sz\u00edtm\u00e9nyek el\u0151\u00e1ll\u00edt\u00e1s\u00e1ban","author":"Chvatal","year":"2016","journal-title":"Gyogyszereszet"},{"key":"10.1016\/j.ejps.2026.107538_bib0015","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ijpharm.2017.01.070","article-title":"Aerodynamic properties and in silico deposition of meloxicam potassium incorporated in a carrier-free DPI pulmonary system","volume":"520","author":"Chvatal","year":"2017","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2026.107538_bib0013","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ijpharm.2019.01.034","article-title":"Formulation and comparison of spray dried non-porous and large porous particles containing meloxicam for pulmonary drug delivery","volume":"559","author":"Chvatal","year":"2019","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2026.107538_bib0012","series-title":"Formulation and Aerodynamic Evaluation of Carrier-Free Dry Powder Inhalation Systems Containing Meloxicam","author":"Chvatal","year":"2019"},{"key":"10.1016\/j.ejps.2026.107538_bib0016","series-title":"Nanomedicine in Pulmonary Delivery","author":"Das","year":"2021"},{"key":"10.1016\/j.ejps.2026.107538_bib0017","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ejpb.2015.07.016","article-title":"Can \u201cextrafine\u201d dry powder aerosols improve lung deposition?","volume":"96","author":"De Boer","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejps.2026.107538_bib0018","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.jcf.2018.07.005","article-title":"Eradication of persistent methicillin-resistant Staphylococcus aureus infection in cystic fibrosis","volume":"18","author":"Dezube","year":"2019","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.ejps.2026.107538_bib0020","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.4209\/aaqr.2015.03.0144","article-title":"Computer modelling as a tool in characterization and optimization of aerosol drug delivery","volume":"15","author":"Farkas","year":"2015","journal-title":"Aerosol Air Qual. Res."},{"key":"10.1016\/j.ejps.2026.107538_bib0019","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.ejps.2016.08.036","article-title":"Numerical simulation of emitted particle characteristics and airway deposition distribution of Symbicort\u00ae Turbuhaler\u00ae dry powder fixed combination aerosol drug","volume":"93","author":"Farkas","year":"2016","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2026.107538_bib0021","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1080\/10837450701703014","article-title":"Vancomycin-triacetyl cyclodextrin interaction products for prolonged drug delivery","volume":"13","author":"Ferrari","year":"2008","journal-title":"Pharm. Dev. Technol."},{"key":"10.1016\/j.ejps.2026.107538_bib0022","article-title":"Human airway epithelial cell lines for in vitro drug transport and metabolism studies","volume":"3","author":"Forbes","year":"2000","journal-title":"Res. Focus"},{"key":"10.1016\/j.ejps.2026.107538_bib0023","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/su13126657","article-title":"Life-cycle assessment of the Breezhaler\u00ae breath-actuated dry powder inhaler","volume":"13","author":"Fulford","year":"2021","journal-title":"Sustainability"},{"key":"10.1016\/j.ejps.2026.107538_bib0024","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.addr.2014.04.005","article-title":"Dry powders for oral inhalation free of lactose carrier particles","volume":"75","author":"Healy","year":"2014","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejps.2026.107538_bib0025","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1513\/pats.200409-046TA","article-title":"Deposition of inhaled particles in the human respiratory tract and consequences for regional targeting in respiratory drug delivery","volume":"1","author":"Heyder","year":"2004","journal-title":"Proc. Am. Thorac. Soc."},{"key":"10.1016\/j.ejps.2026.107538_bib0026","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1089\/jamp.2017.1396","article-title":"Harmonizing the nomenclature for therapeutic aerosol particle size: a proposal","volume":"31","author":"Hillyer","year":"2018","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"key":"10.1016\/j.ejps.2026.107538_bib0027","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.jaerosci.2011.05.007","article-title":"Modelling inhaled particle deposition in the human lung-a review","volume":"42","author":"Hofmann","year":"2011","journal-title":"J. Aerosol Sci."},{"key":"10.1016\/j.ejps.2026.107538_bib0028","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ejps.2017.03.047","article-title":"Significance of breath-hold time in dry powder aerosol drug therapy of COPD patients","volume":"104","author":"Horv\u00e1th","year":"2017","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2026.107538_bib0030","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ejps.2016.03.008","article-title":"Computer modeling of airway deposition distribution of Foster\u00ae NEXThaler\u00ae and Seretide\u00ae Diskus\u00ae dry powder combination drugs","volume":"88","author":"J\u00f3kay","year":"2016","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2026.107538_bib0029","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ijpharm.2017.12.046","article-title":"Probing the particulate microstructure of the aerodynamic particle size distribution of dry powder inhaler combination products","volume":"538","author":"Jetzer","year":"2018","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2026.107538_bib0031","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114561","article-title":"Engineering the right formulation for enhanced drug delivery","volume":"191","author":"Ke","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejps.2026.107538_bib0032","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.ijpharm.2011.06.038","article-title":"Edetate calcium disodium nanoparticle dry powder inhalation: a novel approach against heavy metal decorporation","volume":"416","author":"Kumar","year":"2011","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2026.107538_bib0033","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/pharmaceutics12010055","article-title":"Influence of composition and spray-drying process parameters on carrier-free DPI properties and behaviors in the lung: a review","volume":"12","author":"Lechanteur","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejps.2026.107538_bib0034","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1007\/s12325-019-01066-6","article-title":"Understanding dry powder inhalers: key technical and patient preference attributes","volume":"36","author":"Levy","year":"2019","journal-title":"Adv. Ther."},{"key":"10.1016\/j.ejps.2026.107538_bib0036","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.drudis.2014.09.020","article-title":"Recent advances in controlled pulmonary drug delivery","volume":"20","author":"Liang","year":"2015","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejps.2026.107538_bib0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/pharmaceutics12111025","article-title":"Pulmonary delivery of biological drugs","volume":"12","author":"Liang","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejps.2026.107538_bib0037","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.drudis.2019.09.023","article-title":"Physicochemical properties affecting the fate of nanoparticles in pulmonary drug delivery","volume":"25","author":"Liu","year":"2020","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejps.2026.107538_bib0038","article-title":"Interventions for the eradication of meticillin-resistant Staphylococcus aureus (MRSA) in people with cystic fibrosis","volume":"2022","author":"Lo","year":"2022","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ejps.2026.107538_bib0039","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics16040436","article-title":"Novel dry hyaluronic acid\u2013vancomycin complex powder for inhalation, useful in pulmonary infections associated with cystic fibrosis","volume":"16","author":"Magi","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejps.2026.107538_bib0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/pharmaceutics15020435","article-title":"On the physical stability of leucine-containing spray-dried powders for respiratory drug delivery","volume":"15","author":"Ordoubadi","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejps.2026.107538_bib0041","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.ijpharm.2016.07.003","article-title":"New aspects of developing a dry powder inhalation formulation applying the quality-by-design approach","volume":"511","author":"Pallagi","year":"2016","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2026.107538_bib0042","doi-asserted-by":"crossref","first-page":"466","DOI":"10.3390\/pharmaceutics17040466","article-title":"Optimization, in vitro, and in silico characterization of theophylline inhalable powder using raffinose-amino acid combination as fine Co-spray-dried carriers","volume":"17","author":"Party","year":"2025","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejps.2026.107538_bib0044","first-page":"1","article-title":"Encapsulation of active ingredients in food industry by spray-drying and nano spray-drying technologies","volume":"889","author":"Pi\u00f1\u00f3n-Balderrama","year":"2020","journal-title":"Processes"},{"key":"10.1016\/j.ejps.2026.107538_bib0043","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2010.03.017","article-title":"Formulation strategy and use of excipients in pulmonary drug delivery","volume":"392","author":"Pilcer","year":"2010","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2026.107538_bib0045","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1021\/acs.jced.9b01086","article-title":"Heat capacities of l -alanine, l -valine, l -isoleucine, and l -leucine: experimental and computational study","volume":"65","author":"Pokorn\u00fd","year":"2020","journal-title":"J. Chem. Eng. Data"},{"key":"10.1016\/j.ejps.2026.107538_bib0002","unstructured":"2.9.18. Preparation for inhalation: aerodynamic assessment of fine particles, In European Pharmacopoeia 11.0; 2024; pp. 369\u2013382."},{"key":"10.1016\/j.ejps.2026.107538_bib0046","series-title":"Tracheobronchial Geometry","first-page":"1","author":"Raabe","year":"1976"},{"key":"10.1016\/j.ejps.2026.107538_bib0047","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/cit614","article-title":"Methicillin-resistant Staphylococcus aureus therapy: past, present, and future","volume":"58","author":"Rodvold","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ejps.2026.107538_bib0048","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1086\/600877","article-title":"Vancomycin therapeutic guidelines: a summary of consensus recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists","volume":"49","author":"Rybak","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ejps.2026.107538_bib0049","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3109\/10837450.2010.485320","article-title":"Evaluation of the nano spray dryer B-90 for pharmaceutical applications","volume":"16","author":"Schmid","year":"2011","journal-title":"Pharm. Dev. Technol."},{"key":"10.1016\/j.ejps.2026.107538_bib0050","article-title":"A comprehensive overview of dry powder inhalers for pulmonary drug delivery: challenges, advances, optimization techniques, and applications","volume":"84","author":"Shahin","year":"2023","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.ejps.2026.107538_bib0051","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1080\/17425247.2020.1702643","article-title":"Physical stability of dry powder inhaler formulations","volume":"17","author":"Shetty","year":"2020","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.ejps.2026.107538_bib0052","first-page":"1","article-title":"Dispersibility and storage stability optimization of high dose isoniazid dry powder inhalation formulations with L-leucine or trileucine","volume":"12","author":"Sibum","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejps.2026.107538_bib0053","first-page":"209","article-title":"Enhanced pulmonary delivery of spray-dried theophylline: investigation of the trehalose and amino acid combinations as innovative fine carriers","author":"Soliman","year":"2025","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2026.107538_bib0054","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.cis.2015.05.003","article-title":"Advantages and challenges of the spray-drying technology for the production of pure drug particles and drug-loaded polymeric carriers","volume":"223","author":"Sosnik","year":"2015","journal-title":"Adv. Colloid Interface Sci."},{"key":"10.1016\/j.ejps.2026.107538_bib0055","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.ejpb.2012.10.015","article-title":"The effect of amino acid excipients on morphology and solid-state properties of multi-component spray-dried formulations for pulmonary delivery of biomacromolecules","volume":"83","author":"Sou","year":"2013","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejps.2026.107538_bib0056","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/j.drudis.2018.05.017","article-title":"Current approaches to the discovery of novel inhaled medicines","volume":"23","author":"Strong","year":"2018","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejps.2026.107538_bib0057","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1021\/acs.molpharmaceut.5b00062","article-title":"Pulmonary delivery of vancomycin dry powder aerosol to intubated rabbits","volume":"12","author":"Sullivan","year":"2015","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejps.2026.107538_bib0058","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2013.06.008","article-title":"New perspectives in nanomedicine","author":"Thorley","year":"2013","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2026.107538_bib0059","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2020.105600","article-title":"Enhancement of the extra-fine particle fraction of levofloxacin embedded in excipient matrix formulations for dry powder inhaler using response surface methodology","volume":"156","author":"Tse","year":"2021","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2026.107538_bib0060","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01776-19","article-title":"Phase I, dose-escalating study of the safety and pharmacokinetics of inhaled dry-powder vancomycin (AeroVAnc) in volunteers and patients with cystic fibrosis: a new approach to therapy for methicillin-resistant Staphylococcus aureus","volume":"64","author":"Waterer","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejps.2026.107538_bib0061","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1136\/thoraxjnl-2021-218088","article-title":"Effects of switching from a metered dose inhaler to a dry powder inhaler on climate emissions and asthma control: post-hoc analysis","author":"Woodcock","year":"2022","journal-title":"Thorax"},{"key":"10.1016\/j.ejps.2026.107538_bib0063","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/pharmaceutics12100911","article-title":"Advances in pulmonary drug delivery","volume":"12","author":"Y\u0131ld\u0131z-Pek\u00f6z","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejps.2026.107538_bib0062","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.121457","article-title":"The future of dry powder inhaled therapy: promising or discouraging for systemic disorders?","volume":"614","author":"Ye","year":"2022","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2026.107538_bib0064","doi-asserted-by":"crossref","DOI":"10.1016\/j.cocis.2021.101497","article-title":"Natural and bioinspired excipients for dry powder inhalation formulations","volume":"56","author":"Zillen","year":"2021","journal-title":"Curr. Opin. Colloid Interface Sci."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098726001120?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098726001120?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T05:34:35Z","timestamp":1783056875000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098726001120"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":64,"alternative-id":["S0928098726001120"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2026.107538","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of inhalable extra-fine particles of vancomycin for the treatment of pulmonary methicillin-resistant Staphylococcus aureus infections","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2026.107538","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107538"}}